What Is Wegovy HD, and Why Does It Matter?
Wegovy HD is a new 7.2-milligram strength of semaglutide given once a week as an injection under the skin. It is approved to help adults lose excess weight and keep it off if you have obesity, or if you are overweight with at least one weight‑related health problem. Semaglutide belongs to a class of medicines called glucagon‑like peptide‑1 (GLP‑1) receptor agonists. The FDA based its decision on data showing more average weight loss with this higher dose compared with earlier Wegovy doses, with side effects that were in line with what is already known for semaglutide. The review used a pilot program that allowed closer communication and rolling review to help speed the review timeline for a public health need. This new dose adds to the existing Wegovy injection options of 1.7 milligrams and 2.4 milligrams for maintenance dosing. The higher 7.2-milligram dose may be clinically indicated in patients who tolerate the 2.4-milligram dose for at least four weeks, but additional weight reduction is clinically indicated.
Why Was It Approved?
The FDA’s decision reflects evidence that the 7.2-milligram dose led to more average weight loss than earlier Wegovy doses, with side effects that were similar to the known profile of semaglutide. In studies reported by the company, adults with obesity taking semaglutide 7.2 milligrams lost about 20.7% of their body weight on average, and about 1 in 3 achieved at least 25% weight loss. In adults with type 2 diabetes (T2D), average weight loss was about 14.1% with the 7.2-milligram dose. In adults who had both obesity and T2D, blood‑sugar lowering at 7.2 milligrams looked similar to lower‑dose semaglutide.
Wegovy’s broader label is supported by results across several conditions. In adults who already had cardiovascular disease and either obesity or overweight (without type 1 or type 2 diabetes), the once‑weekly injection reduced the risk of a first major heart event compared with placebo. A clear benefit for cardiovascular death was not confirmed, and effects on heart failure are not established.
For weight management, both the injection and the tablets led to more weight loss than placebo in adults, and the injection lowered body mass index (BMI) in teens 12 and older with obesity. In adults with MASH, the injection improved key liver tissue measures compared with placebo, including more people with resolution of liver inflammation without worse scarring, and some with less scarring without worse inflammation.
The most common side effects across studies were stomach‑ and gut‑related, such as nausea, vomiting, diarrhea, constipation, and belly pain. Reports of altered skin sensations happened more often with higher doses and usually got better on their own or after lowering the dose; a small number of people stopped treatment. These are not all possible side effects.
What Do I Need to Know?
Inject Wegovy once a week on the same day each week. You can take it with or without food. If you tolerate 2.4 milligrams for at least four weeks and you and your health care provider decide you need more weight loss, you may increase to a maximum of 7.2 milligrams once weekly. With the single‑use pen, you will hear two clicks. Keep steady pressure until the yellow bar stops moving, which signals the dose is finished. The 7.2-milligram single‑dose pen is expected in the U.S. in April 2026.
Wegovy has a boxed warning about a possible risk of thyroid C‑cell tumors seen in animal studies. Do not use it if you or a family member has had medullary thyroid carcinoma (MTC) or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). Do not use it if you are allergic to semaglutide or any ingredient. Serious risks can include sudden pancreas inflammation and gallbladder problems. A faster resting heart rate has been reported. Wegovy can lower blood sugar and may cause hypoglycemia, especially if you also take insulin or a sulfonylurea. Your health care provider may change those medicines.
Because Wegovy slows stomach emptying, it can affect how some pills are absorbed and may raise the chance of food or liquid coming back up during anesthesia or deep sedation. Tell every health care provider before any procedure. Wegovy may harm a fetus. Stop using it when pregnancy is recognized and stop at least two months before a planned pregnancy. Do not breastfeed while using.
Inject under the skin of the belly, thigh, or upper arm. Rotate the site each week. If you miss a weekly injection and the next dose is more than two days away, take it when you remember. If less than two days remain, skip the missed dose and take your next dose on the usual day. Do not use Wegovy with any other semaglutide product or another GLP‑1 receptor agonist. Use Wegovy with a reduced‑calorie diet and increased physical activity as directed by your health care provider.